Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus - Abbott

Drug Profile

Everolimus - Abbott

Alternative Names: Absorb; Affinitor; Affinitor Dispersible; Afinitor; Afinitor DISPERZ; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Synergy-everolimus-eluting-stent; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Amgen; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Genentech; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of California, Davis; University of Pittsburgh; University of Sydney; University of Texas M. D. Anderson Cancer Center; VU University Medical Center; Yale University
  • Class Antineoplastics; Macrolides; Polyenes
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Astrocytoma; Angiomyolipoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Partial epilepsies; Renal cell carcinoma; Renal transplant rejection
  • Phase III Autosomal dominant polycystic kidney disease; Liver cancer; Myocardial infarction
  • Phase II Brain metastases; Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Meningioma; Neurofibromatoses; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma; Sarcoma; Tuberous sclerosis; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Colorectal cancer; Oesophageal cancer; Respiratory tract infections
  • Phase I Haematological malignancies; Solid tumours
  • No development reported Cervical cancer; Mantle-cell lymphoma; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Thyroid cancer
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 06 Nov 2019 Phase-II development is ongoing in USA (NCT02201212)
  • 09 Oct 2019 Suspended - Phase-II for Breast cancer (Late-stage disease, Neoadjuvant therapy) in USA (PO) (NCT02236572)
  • 02 Sep 2019 Novartis terminates a phase II trial in Gastrointestinal cancer, Pancreatic cancer and Neuroendocrine tumours in Greece (NCT01648465)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top